Announcements

19 January 2024
Journal of Personalized Medicine | Most Cited Papers in 2023


1. “Predicting the Onset of Diabetes with Machine Learning Methods”
by Chun-Yang Chou, Ding-Yang Hsu and Chun-Hung Chou
J. Pers. Med. 2023, 13(3), 406; https://doi.org/10.3390/jpm13030406
Available online: https://www.mdpi.com/2075-4426/13/3/406

2. “A Review of the Role of Artificial Intelligence in Healthcare”
by Ahmed Al Kuwaiti, Khalid Nazer, Abdullah Al-Reedy, Shaher Al-Shehri, Afnan Al-Muhanna, Arun Vijay Subbarayalu, Dhoha Al Muhanna and Fahad A. Al-Muhanna
J. Pers. Med. 2023, 13(6), 951; https://doi.org/10.3390/jpm13060951
Available online: https://www.mdpi.com/2075-4426/13/6/951

3. “The Rationale for Vitamin, Mineral, and Cofactor Treatment in the Precision Medical Care of Autism Spectrum Disorder”
by Neluwa-Liyanage R. Indika, Richard E. Frye, Daniel A. Rossignol, Susan C. Owens, Udara D. Senarathne, Andreas M. Grabrucker, Rasika Perera, Marielle P. K. J. Engelen and Nicolaas E. P. Deutz
J. Pers. Med. 2023, 13(2), 252; https://doi.org/10.3390/jpm13020252
Available online: https://www.mdpi.com/2075-4426/13/2/252

4. “Three-Dimensional Accuracy and Stability of Personalized Implants in Orthognathic Surgery: A Systematic Review and a Meta-Analysis”
by Alexandru Diaconu, Michael Boelstoft Holte, Gabriele Berg-Beckhoff and Else Marie Pinholt
J. Pers. Med. 2023, 13(1), 125; https://doi.org/10.3390/jpm13010125
Available online: https://www.mdpi.com/2075-4426/13/1/125

5. “Efficacy and Safety of Distal Radial Access for Transcatheter Arterial Chemoembolization (TACE) of the Liver”
by Roberto Minici, Raffaele Serra, Marco Giurdanella, Marisa Talarico, Maria Anna Siciliano, Gianpaolo Carrafiello and Domenico Laganà
J. Pers. Med. 2023, 13(4), 640; https://doi.org/10.3390/jpm13040640
Available online: https://www.mdpi.com/2075-4426/13/4/640

6. “Is Ozone a Valid Adjuvant Therapy for Periodontitis and Peri-Implantitis? A Systematic Review”
by Francesco D’Ambrosio, Mario Caggiano, Alfonso Acerra, Massimo Pisano and Francesco Giordano
J. Pers. Med. 2023, 13(4), 646; https://doi.org/10.3390/jpm13040646
Available online: https://www.mdpi.com/2075-4426/13/4/646

7. “Biomarkers as Prognostic Predictors and Therapeutic Guide in Critically Ill Patients: Clinical Evidence”
by Rosa Méndez Hernández and Fernando Ramasco Rueda
J. Pers. Med. 2023, 13(2), 333; https://doi.org/10.3390/jpm13020333
Available online: https://www.mdpi.com/2075-4426/13/2/333

8. “Long COVID: Clinical Framing, Biomarkers, and Therapeutic Approaches”
by Valeria Conti, Graziamaria Corbi, Francesco Sabbatino, Domenico De Pascale, Carmine Sellitto, Berenice Stefanelli, Nicola Bertini, Matteo De Simone, Luigi Liguori, Ilenia Di Paola et al.
J. Pers. Med. 2023, 13(2), 334; https://doi.org/10.3390/jpm13020334
Available online: https://www.mdpi.com/2075-4426/13/2/334

9. “Multi-Modal Stacking Ensemble for the Diagnosis of Cardiovascular Diseases”
by Taeyoung Yoon and Daesung Kang
J. Pers. Med. 2023, 13(2), 373; https://doi.org/10.3390/jpm13020373
Available online: https://www.mdpi.com/2075-4426/13/2/373

10. “COVID-19 and New-Onset Psychosis: A Comprehensive Review”
by Lorenzo Moccia, Georgios D. Kotzalidis, Giovanni Bartolucci, Sara Ruggiero, Laura Monti, Marco Biscosi, Beatrice Terenzi, Ottavia M. Ferrara, Marianna Mazza, Marco Di Nicola et al.
J. Pers. Med. 2023, 13(1), 104; https://doi.org/10.3390/jpm13010104
Available online: https://www.mdpi.com/2075-4426/13/1/104

11. “Ethical Implications of Chatbot Utilization in Nephrology”
by Oscar A. Garcia Valencia, Supawadee Suppadungsuk, Charat Thongprayoon, Jing Miao, Supawit Tangpanithandee, Iasmina M. Craici and Wisit Cheungpasitporn
J. Pers. Med. 2023, 13(9), 1363; https://doi.org/10.3390/jpm13091363
Available online: https://www.mdpi.com/2075-4426/13/9/1363

12. “A Summary on Tuberculosis Vaccine Development—Where to Go?”
by Fan Jiang, Tiehui Sun, Peng Cheng, Jie Wang and Wenping Gong
J. Pers. Med. 2023, 13(3), 408; https://doi.org/10.3390/jpm13030408
Available online: https://www.mdpi.com/2075-4426/13/3/408

13. “A Multi-Task Convolutional Neural Network for Semantic Segmentation and Event Detection in Laparoscopic Surgery”
by Giorgia Marullo, Leonardo Tanzi, Luca Ulrich, Francesco Porpiglia and Enrico Vezzetti
J. Pers. Med. 2023, 13(3), 413; https://doi.org/10.3390/jpm13030413
Available online: https://www.mdpi.com/2075-4426/13/3/413

14. “Use of Telemedicine Healthcare Systems in Children and Adolescents with Chronic Disease or in Transition Stages of Life: Consensus Document of the Italian Society of Telemedicine (SIT), of the Italian Society of Preventive and Social Pediatrics (SIPPS), of the Italian Society of Pediatric Primary Care (SICuPP), of the Italian Federation of Pediatric Doctors (FIMP) and of the Syndicate of Family Pediatrician Doctors (SIMPeF)”
by Susanna Esposito, Cristiano Rosafio, Francesco Antodaro, Alberto Argentiero, Marta Bassi, Paolo Becherucci, Fabio Bonsanto, Andrea Cagliero, Giulia Cannata, Fabio Capello et al.
J. Pers. Med. 2023, 13(2), 235; https://doi.org/10.3390/jpm13020235
Available online: https://www.mdpi.com/2075-4426/13/2/235

15. “Mechanisms of Allergen Immunotherapy and Potential Biomarkers for Clinical Evaluation”
by Umit M. Sahiner, Mattia Giovannini, Maria M. Escribese, Giovanni Paoletti, Enrico Heffler, Montserrat Alvaro Lozano, Domingo Barber, Giorgio Walter Canonica and Oliver Pfaar
J. Pers. Med. 2023, 13(5), 845; https://doi.org/10.3390/jpm13050845
Available online: https://www.mdpi.com/2075-4426/13/5/845

16. “Immunoinformatic-Based Multi-Epitope Vaccine Design for Co-Infection of Mycobacterium tuberculosis and SARS-CoV-2”
by Cong Peng, Fengjie Tang, Jie Wang, Peng Cheng, Liang Wang and Wenping Gong
J. Pers. Med. 2023, 13(1), 116; https://doi.org/10.3390/jpm13010116
Available online: https://www.mdpi.com/2075-4426/13/1/116

17. “The Association between Alexithymia and Social Media Addiction: Exploring the Role of Dysmorphic Symptoms, Symptoms Interference, and Self-Esteem, Controlling for Age and Gender”
by Alessio Gori and Eleonora Topino
J. Pers. Med. 2023, 13(1), 152; https://doi.org/10.3390/jpm13010152
Available online: https://www.mdpi.com/2075-4426/13/1/152

18. “The Role of BDNF as a Biomarker in Cognitive and Sensory Neurodegeneration”
by Anna Pisani, Fabiola Paciello, Valeria Del Vecchio, Rita Malesci, Eugenio De Corso, Elena Cantone and Anna Rita Fetoni
J. Pers. Med. 2023, 13(4), 652; https://doi.org/10.3390/jpm13040652
Available online: https://www.mdpi.com/2075-4426/13/4/652

19. “The Role of Cold Atmospheric Plasma in Wound Healing Processes in Critically Ill Patients”
by Tatiana Bolgeo, Antonio Maconi, Menada Gardalini, Denise Gatti, Roberta Di Matteo, Marco Lapidari, Yaroslava Longhitano, Gabriele Savioli, Andrea Piccioni and Christian Zanza
J. Pers. Med. 2023, 13(5), 736; https://doi.org/10.3390/jpm13050736
Available online: https://www.mdpi.com/2075-4426/13/5/736

20. “Epidemiology and Risk Factors of UTIs in Children—A Single-Center Observation”
by Maria Daniel, Hanna Szymanik-Grzelak, Janusz Sierdziński, Edyta Podsiadły, Magdalena Kowalewska-Młot and Małgorzata Pańczyk-Tomaszewska
J. Pers. Med. 2023, 13(1), 138; https://doi.org/10.3390/jpm13010138
Available online: https://www.mdpi.com/2075-4426/13/1/138

10 January 2024
Meet Us at the 53rd Annual Meeting of the Japanese Society for Spine Surgery and Related Research, 18–20 April 2024, Yokohama, Japan

MDPI will attend the 53rd Annual Meeting of the Japanese Society for Spine Surgery and Related Research as an exhibitor. This conference will be held in Yokohama, Japan, from 18 to 20 April 2024.

The following MDPI journals will be represented:

If you are attending this conference, please feel free to start a conversation with us at our booth. Our delegates look forward to meeting you in person and answering any questions that you may have.

For more information about the conference, please visit https://site2.convention.co.jp/jssr2024/index_en.html.

2 January 2024
MDPI Insights: The CEO's Letter #7 - Nobel Laureates Entrust MDPI with Their Research

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

Nobel Prize Laureates Entrust MDPI with Their Research

The Nobel Prize stands as a hallmark of distinction, honouring ground-breaking research across disciplines. Annually, the Nobel Prizes are awarded in six categories: Physics, Chemistry, Medicine or Physiology, Literature, Peace, and Economic Sciences.

Through the years, renowned scholars have entrusted MDPI with their work. As at December 2023, 26 Nobel laureates have contributed to more than 75 articles across 25 MDPI journals, including: Antibiotics, Applied Sciences, Biology, Biomedicines, Cancers, Catalysts, Cells, Crystals, Entropy, Games, IJMS, Life, Materials, Micromachines, Molecules, Pharmaceuticals, PharmaceuticsPhotonics, Quantum Beam Science, Remote Sensing, Sensors, Solids, Universe, Vaccines, and Viruses.

The best of the best trust us with their work.

Nobel Prize Laureates Who Have Published with MDPI

We are proud to list the names of Pierre Agostini, Hiroshi Amano, Werner Arber, Aaron Ciechanover, Robert H. Grubbs, Oliver Hart, Gerard ‘t Hooft, Michael Houghton, Harald zur Hausen, Katalin Karikó, Jean-Marie Lehn, Gérard Mourou, Ferid Murad, Shuji Nakamura, William Nordhaus, Kostya S. Novoselov, Giorgio Parisi, Charles M. Rice, Alvin E. Roth, Donna Strickland, K. Barry Sharpless, George F. Smoot, Anne L’Huillier, Drew Weissman, Kurt Wüthrich, Ada Yonath.

The privilege of hosting such contributors resonates deeply with our editorial teams. For instance, in this interview, the Editor-in-Chief (EiC) of Universe speaks on the significance of publishing a paper by Nobel laureate Gerard ’t Hooft within the journal.

2023 Nobel Prize Winners Published by MDPI

Nobel Prize Winners, 2023: Katalin Karikó, Drew Weissman, Anne L’Huillier (Ill. Niklas Elmehed © Nobel Prize Outreach)

Three laureates from the 2023 Nobel Prize cohort have trusted MDPI as their publishing platform. Notably, in a 2022 Pharmaceutics paper, molecular biologist Katalin Karikó and her team presented a methodology for evaluating mRNA capping efficiency, pivotal for therapeutic applications. Pharmaceutics had previously dedicated a Special Issue to “mRNA Therapeutics: A Themed Issue in Honor of Professor Katalin Karikó”, spotlighting ten articles from August 2021 to February 2022.

In the journal Vaccines, Professor Drew Weissman, collaborating with scholars from Pennsylvania University and George Mason University, contributed an influential review titled “Nanomaterial Delivery Systems for mRNA Vaccines”. His collaborative efforts spanned five papers across MDPI journals between 2021 and 2023.

Furthermore, Anne L'Huillier of Lund University, only the fifth female recipient of the Physics Prize, co-authored an article in Applied Sciences focusing on "Advanced EUV and X-Ray Optics". Similarly, Pierre Agostini, an Emeritus Professor from Ohio State University, co-authored an article featured in the special issue "Attosecond Science and Technology: Principles and Applications".

We extend heartfelt congratulations to all Nobel Prize laureates and express sincere gratitude for their confidence in MDPI as a platform for their scholarly contributions.

Read more:

Impactful Research

MDPI Journals Newly Indexed in 2023

The aim of indexing is to enhance the quality and credibility of published research, ensuring that researchers access the most credible resources available. While the principle behind citation indexing is straightforward, it remains one of the most dependable methods for tracking an idea's evolution across various scientific disciplines.

Throughout the year, MDPI works to expand the reach of our publications across premier multidisciplinary databases like Web of Science, Scopus, EBSCO, and ProQuest. This initiative is spearheaded by MDPI's Indexing team, under the leadership of Dr. Constanze Schelhorn.

In 2023, MDPI achieved 54 new acceptances in Scopus, 29 in Web of Science, 52 in EBSCO, and 83 in DOAJ: Directory of Open Access Journals.

The team prioritizes ensuring that our journals feature in numerous specialized databases, including PMC, PubMed, MEDLINE, Inspec, CAS, and FSTA, among others. Currently, MDPI collaborates with over 65 renowned international databases, consistently enhancing our database affiliations annually.

MDPI’s journals are indexed in all major global databases.

Furthermore, we collaborate with universities and government organizations to list our journals in country-specific ranking lists and relevant institutional repositories. This ensures compliance with requirements often set by funders or institutions for authors to publish in specific journals.

Web of Science Adds 24 MDPI Journals to Emerging Sources Citation Index (ESCI)

Clarivate recently analysed MDPI’s new journals, resulting in 24 journals, mainly established in 2020, being added to the ESCI in November and December 2023. Additionally, five journals passed this assessment earlier in the year. For a complete list of our journals in Web of Science, refer here. Journals in the ESCI meet 24 quality criteria, ensuring editorial rigor. They may be considered for inclusion in broader indices like the Science Citation Index Expanded (SCIE), the Social Sciences Citation Index (SSCI), or the Arts and Humanities Citation Index (AHCI), based on four impact criteria.

Read more:

Inside MDPI

MDPI Appoints New Chief Operating Officer (COO)

Alistair Freeland returned to MDPI and assumed the role of Chief Operating Officer in November 2023, a position he previously held from 2013 to 2019. He succeeds Dr. Yu Lin, who will remain a member of MDPI’s Board of Directors, overseeing significant financial decisions for the company. I would like to express my sincere thanks to Dr. Yu Lin for his service as COO.

Alistair brings extensive experience not only in scholarly publishing but also in technology and business management. Prior to rejoining MDPI, he was associated with SIX Group, the entity responsible for Switzerland's financial market infrastructure. There, he played a pivotal role in developing the blockchain-based platform SDX (SIX Digital Exchange), which has gained traction among major Swiss banks and the Swiss National Bank.

As COO, Alistair will collaborate with the MDPI management team to improve the practices and services we offer to scholarly communities. I am pleased to welcome Alistair back to MDPI and look forward to his contributions going forward.

Coming Together for Science

MDPI’s 2024 In-Person Academic Events Schedule

MDPI's Conference Team is dedicated to organizing and hosting in-person academic events across Europe, Asia-Pacific, and North America. We recognize conferences as invaluable platforms for scientific collaboration, scholarly exchange, discussions on contemporary topics, networking, and forging collaborations.

Here's a glimpse of the notable events we currently have scheduled for 2024:

14–16 February, 2024
Viruses 2024 – A World of Viruses
Location: Barcelona, Spain
We are honoured to feature Nobel Prize laureate Dr. Charles M. Rice and ‘Distinguished Senior Virologist’ Prof. Luis Enjuanes as keynote speakers for this 5th edition.
Event details

24–26 April, 2024
4th MMCS – Harnessing the Power of New Drug Modalities 
Location: Barcelona, Spain
Esteemed speakers include Prof. Arun K. Ghosh, the mind behind the Darunavir molecule, and Prof. Paul Brennan, CSO of Alzheimer's Research UK Oxford Drug Discovery Institute.
Event details

28–31 May, 2024
Polymers 2024 – Polymers for a Safe and Sustainable Future
Location:
Athens, Greece
We look forward to welcoming renowned experts like Prof. Damià Barceló, Prof. Minna Hakkareinen, and Prof. Armando J. D. Silvestre to this event.
Event details

1–4 August, 2024
The 1st International Conference on AI Sensors & The 10th International Symposium on Sensor Science
Location: Singapore
The AI Sensors 2024 Conference will unite innovators and experts in the realms of sensors, sensing technology, and artificial intelligence.
Event details

Upcoming events with details to be announced:

  • September 2024, Materials 2024 – Basel, Switzerland
  • 1921 September 2024, International Conference on Nanomaterials Sciences 2024 – Beijing, China
  • October 2024, ncRNA 2024 – Basel, Switzerland
  • November 2024, Pharmaceuticals 2024 – Barcelona, Spain
  • 2226 November 2024, International Conference on Science of Electronics – Wuhan, China
  • Stay tuned for more details on the Sustainable Publishing Forum 2024.

Click here for all upcoming MDPI events.

Organize Your Event with MDPI’s Sciforum

Sciforum is MDPI’s platform dedicated to the organization of scientific events. In line with our mission to promote science, Sciforum supports scholars, societies, research networks, and universities at all stages of organizing in-person events, virtual events and webinars. Our platforms are efficient, user-friendly, and cost-effective. We handle all steps related to event management. Contact us for details.

Closing Thoughts

Reflecting on 2023 and Looking Ahead to 2024

As we approach 2024, I reflect on the incredible journey we’ve had together at MDPI this year. The past 12 months have been marked by ambitious projects and initiatives to improve our internal processes, and a commitment to continue delivering top-notch services to our stakeholders. I’d like to thank each and every one of our staff members for contributing to the positive experiences our stakeholders have reported in our surveys. Your dedication to speed, efficiency, and effective communication with our stakeholders is very much recognized and appreciated.

Becoming a stronger organisation

While we have encountered challenges in 2023, it’s important to understand that these are a part of our growth process. Difficulties provide us with opportunities to reflect, address problems at their roots, and ultimately evolve into a stronger organization. Our stakeholders expect us to overcome tough times, and it’s an expectation that we have for ourselves.

I extend my sincere appreciation to every MDPI employee, from our editorial office and IT department to marketing, indexing, IOAP, societies, Scientific Office board, products, production, conferences, finance, operations, admin, and beyond. To our newest team members, a warm welcome; to our longstanding colleagues, your dedication is invaluable.

“I am committed to taking MDPI to a new level of excellence.”

Interacting with many of you during my visits to our offices and representing MDPI at external events has been a personal highlight. I am deeply grateful to Dr. Lin for entrusting me with the role of CEO of MDPI. Looking forward, I am committed to working closely with our management team to lead MDPI and take it to a new level of excellence, aiming to establish it as the most trusted publisher in open access worldwide. This is a collective endeavour, with each of us shaping MDPI’s reputation. I therefore encourage us to take pride in our work, as it represents not only our craft but also MDPI as a whole.

Accountability and communication

As we look forward to 2024, there’s a lot to be excited about. Together, we’ll navigate challenges, seize growth opportunities, and refine our practices. To solidify MDPI’s position as the premier open access publisher globally, we must bolster accountability, improve stakeholder communication, share MDPI’s best practices, champion the open access philosophy, and educate stakeholders about our mission, methodologies, and motivations.

Thank you for engaging with the CEO Letter over the past six months of 2023. I will continue to release this newsletter as a method of sharing the great work being done at MDPI. Please feel free to connect directly with any insights or questions.

Here’s to a joyous and prosperous 2024!

Stefan Tochev
Chief Executive Officer
MDPI AG

25 December 2023
Journal of Personalized Medicine | Top 10 Cited Papers in 2022 in the Section “Omics/Informatics”


We are pleased to invite you to read the top 10 cited papers in 2022 in Journal of Personalized Medicine (ISSN: 2075-4426) in the Section “Omics/Informatics”. The list of papers is as follows:

1. “Global Challenges to Public Health Care Systems during the COVID-19 Pandemic: A Review of Pandemic Measures and Problems”
by Roxana Filip, Roxana Gheorghita Puscaselu, Liliana Anchidin-Norocel, Mihai Dimian and Wesley K. Savage
J. Pers. Med. 2022, 12(8), 1295; https://doi.org/10.3390/jpm12081295
Available online: https://www.mdpi.com/2075-4426/12/8/1295

2. “Dysregulated miRNAs as Biomarkers and Therapeutical Targets in Neurodegenerative Diseases”
by Giulia Gentile, Giovanna Morello, Valentina La Cognata, Maria Guarnaccia, Francesca Luisa Conforti and Sebastiano Cavallaro
J. Pers. Med. 2022, 12(5), 770; https://doi.org/10.3390/jpm12050770
Available online: https://www.mdpi.com/2075-4426/12/5/770

3. “CDK1 and HSP90AA1 Appear as the Novel Regulatory Genes in Non-Small Cell Lung Cancer: A Bioinformatics Approach”
by Nirjhar Bhattacharyya, Samriddhi Gupta, Shubham Sharma, Aman Soni, Sali Abubaker Bagabir, Malini Bhattacharyya, Atreyee Mukherjee, Atiah H. Almalki, Mustfa F. Alkhanani, Shafiul Haque et al.
J. Pers. Med. 2022, 12(3), 393; https://doi.org/10.3390/jpm12030393
Available online: https://www.mdpi.com/2075-4426/12/3/393

4. “miR-155: A Potential Biomarker for Predicting Mortality in COVID-19 Patients”
by Reut Kassif-Lerner, Keren Zloto, Nadav Rubin, Keren Asraf, Ram Doolman, Gidi Paret and Yael Nevo-Caspi
J. Pers. Med. 2022, 12(2), 324; https://doi.org/10.3390/jpm12020324
Available online: https://www.mdpi.com/2075-4426/12/2/324

5. “Computational Models for Clinical Applications in Personalized Medicine—Guidelines and Recommendations for Data Integration and Model Validation”
by Catherine Bjerre Collin, Tom Gebhardt, Martin Golebiewski, Tugce Karaderi, Maximilian Hillemanns, Faiz Muhammad Khan, Ali Salehzadeh-Yazdi, Marc Kirschner, Sylvia Krobitsch, EU-STANDS4PM consortium and Lars Kuepfer
J. Pers. Med. 2022, 12(2), 166; https://doi.org/10.3390/jpm12020166
Available online: https://www.mdpi.com/2075-4426/12/2/166

6. “The Penn Medicine BioBank: Towards a Genomics-Enabled Learning Healthcare System to Accelerate Precision Medicine in a Diverse Population”
by Anurag Verma, Scott M. Damrauer, Nawar Naseer, JoEllen Weaver, Colleen M. Kripke, Lindsay Guare, Giorgio Sirugo, Rachel L. Kember, Theodore G. Drivas, Scott M. Dudek et al.
J. Pers. Med. 2022, 12(12), 1974; https://doi.org/10.3390/jpm12121974
Available online: https://www.mdpi.com/2075-4426/12/12/1974

7. “Three-Dimensional Semantic Segmentation of Diabetic Retinopathy Lesions and Grading Using Transfer Learning”
by Natasha Shaukat, Javeria Amin, Muhammad Sharif, Faisal Azam, Seifedine Kadry and Sujatha Krishnamoorthy
J. Pers. Med. 2022, 12(9), 1454; https://doi.org/10.3390/jpm12091454
Available online: https://www.mdpi.com/2075-4426/12/9/1454

8. “Image Analysis in Digital Pathology Utilizing Machine Learning and Deep Neural Networks”
by Paris Amerikanos and Ilias Maglogiannis
J. Pers. Med. 2022, 12(9), 1444; https://doi.org/10.3390/jpm12091444
Available online: https://www.mdpi.com/2075-4426/12/9/1444

9. “Epigenetics in Precision Nutrition”
by Xiang Li and Lu Qi
J. Pers. Med. 2022, 12(4), 533; https://doi.org/10.3390/jpm12040533
Available online: https://www.mdpi.com/2075-4426/12/4/533

10. “Personalized Immunotherapies for Type 1 Diabetes: Who, What, When, and How?”
by Claire Deligne, Sylvaine You and Roberto Mallone
J. Pers. Med. 2022, 12(4), 542; https://doi.org/10.3390/jpm12040542
Available online: https://www.mdpi.com/2075-4426/12/4/542

15 December 2023
Journal of Personalized Medicine | Highly Cited Special Issues in the Section “Mechanisms of Diseases” in 2022


We are pleased to invite you to read the highly cited Special Issues in 2022 in the Journal of Personalized Medicine (JPM, ISSN: 2075-4426), in the Section “Mechanisms of Diseases”. We hope this announcement will provide useful information for this field.

The Special Issues list is as follows:

Personalized Medicine for COVID-19 Patients-Clinical Considerations

Edited by Dr. Paraskevi Katsaounou, Prof. Dr. Dimitrios B. Georgopoulos and Dr. Nikoletta Rovina

Views: 75000+ | Cited by 230+

Cardiovascular Disease Prevention in the Era of Personalized Medicine

Edited by Dr. Konstantinos Tziomalos

Views: 49000+ | Cited by 150+

Personalized Medicine in the Field of Inflammatory Skin Disorders

Edited by Dr. Mircea Tampa, Prof. Dr. Monica Neagu, Prof. Dr. Constantin Caruntu and Prof. Dr. Simona Roxana Georgescu

Views: 48000+ | Cited by 190+

Personalized Medicine for Parkinson's Disease: New Concepts and Future of Individualized Management

Edited by Dr. Nataliya Titova and Prof. Dr. Kallol Ray Chaudhuri

Views: 44000+ | Cited by 90+

Asthma: From Phenotypes to Personalized Medicine

Edited by Prof. Dr. Petros Bakakos

Views: 26000+ | Cited by 70+

Personalized Molecular Neurobiology of Brain Mapping of Global Pain and Mental Illness

Edited by Prof. Dr. Kenneth Blum, Dr. Babak Kateb, Dr. Vicky Yamamoto, Prof. Dr. Igor Elman, Dr. Mark S. Gold and Dr. Kai-Uwe Lewandrowski

Views: 37000+ | Cited by 60+

You are welcome to view all the Special Issues and submit relevant papers to the Journal of Personalized Medicine. If you have any questions, you can contact the Editorial Office at jpm@mdpi.com.

Journal of Personalized Medicine Editorial Office

30 November 2023
MDPI Insights: The CEO's Letter #6 - MDPI Spain Summit and ResearchGate

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

MDPI Spain Summit


Stefan Tochev (CEO, MDPI) gives the opening speech at the MDPI Spain Summit.

On Friday 10 November 2023 I was in Barcelona, Spain, to deliver the opening presentation and participate in a panel at MDPI’s Spain Summit, a two-day event, inspired by our salon events in China.

With 16 Editors-in-Chief (EiCs) and 20 Editorial Board Members (EBMs) in attendance, the event, organized by our conference team and Barcelona office, featured presentations on open access (OA), MDPI, and publishing market trends in Spain.

The event provided a great opportunity to engage with stakeholders from various MDPI journals, including Nutrients, Vaccines, Buildings, IJMS, and others. We were able to gather feedback and have open conversations around manuscript quality, the peer-review process, and journal development, as well as accreditation agencies.

The main objective of this Summit was to bring together Editors representing MDPI journals across various disciplines within Spanish universities and research centers, primarily from the Barcelona area. The aim was to facilitate an open and fruitful discussion regarding the development of their journals, the future of OA in Spain, and to provide meaningful interactions and networking opportunities.

Connecting with Editorial Board Members


Stefan Tochev in conversation with Summit participants: "Our EBMs are passionate about the journals they serve."

Interacting with our EBMs in person provides a valuable opportunity to show how important it is to us to connect with them, hear their perspectives on their journals and learn more about their own experience collaborating with MDPI.

From my conversations, it was clear that our EBMs are passionate about the journals they serve. I know the advice they provide may sometimes involve just small tweaks, but these can lead to important improvements. As the saying goes, small hinges swing open big doors.

As at November 2023, MDPI has over 6,300 EBMs affiliated with Spanish institutions, with more than 30 of them serving as EiCs or section EiCs. Furthermore, over 68,000 Spanish scholars have contributed as reviewers in MDPI journals.

Open Access in Spain

In 2023, Spain implemented legislation mandating immediate OA for all publicly funded research, aligning with the EU’s Plan S initiative to expedite the transition to OA. The Spanish government also approved a four-year, €23.8 million annual budget for the first national OA strategy, aiming to make publicly funded research freely accessible upon publication. This strategy aims to strengthen the quality and transparency of research in Spain, and to help promote movement towards a digital, low-carbon economy.

For further details of Spain's OA policy and the history of government mandates, click here.

Spain has already seen a notable decline in subscription-only articles, decreasing by 62% over a 10-year period, while gold OA increased by 42%. Green OA slightly decreased, suggesting a shift towards publishing in gold OA journals rather than traditional subscription-based ones. Here are some statistics from Scopus. 

A big thank-you to the various MDPI teams, including our conference team and the Barcelona office, for organizing this very successful event!


MDPI colleagues from various offices gathered to host and support the first MDPI Spain Summit, in Barcelona, Spain.

I think this type of gathering has the potential to become an annual event in various locations. For example, Manchester could be an option, as we have over 30 EiCs and over 3,000 EBMs in the UK, a top market for MDPI that publishes high-quality research.

Impactful Research

769 Editorial Board Members of MDPI Journals Recognized as Highly Cited Researchers in 2023

Congratulations to our 769 Editorial Board Members from 40 countries/territories who have been awarded Highly Cited Researcher status for 2023 by Clarivate. This recognition is based on their outstanding scientific research contributions and significant influence in various fields, as evidenced by Web of Science data.

Click here to view the full list of 769 Editorial Board Members.

Clarivate's Highly Cited ResearchersTM list identifies individuals with exceptional impact in scientific and social science domains over the past decade. Their papers rank in the top 1% of citations in 21 fields analysed in ‘Essential Science Indicators,’ showcasing their substantial influence.

This year, 7,125 Highly Cited Researcher 2023 designations were issued to 6,849 individuals from 67 countries, representing just 1 in 1,000 researchers worldwide.

These researchers demonstrate exceptional influence, representing a small fraction of contributors pushing the boundaries of knowledge, contributing to global well-being, sustainability, and security.

Congratulations to these scholars for their remarkable achievement: we are honoured to have them on board with our journals!

Inside MDPI

Corporate Marketing and Communications Strategy Session


Members of MDPI’s Corporate Marketing & Communications team.

For the past few years, I have led the Corporate Marketing & Communications department in our annual strategy session.

This typically involves 2–3 days of focused sessions covering key topics including budgeting, hiring targets, campaign reviews, and planning for the upcoming year, department strategy, and structure.

We are constantly exploring ways to optimize the Corporate Marketing & Communications department to support MDPI’s primary objectives and better convey the MDPI story while serving the scholarly community.

The strategy session also serves as a team-building activity, during which the team voted on bowling!

Strategy Session

In this strategy session, we looked at how to align our teams in order to better streamline our content with our campaigns, build a dedicated marketing team to strategically support our core MDPI products, expand our communications teams and functionalities to focus on company-critical campaigns and press releases, align our new brand design system with our marketing initiatives, set up a community and engagement team to support various teams with their outreach and communication efforts, and increase our use of data in the evaluation of campaign performance.

To grow in these areas, we will be hiring for various positions, including those of Public Relations Manager, Communications Manager, Internal Communications Manager, Campaign Manager, Marketing Associate, and Editorial Engagement Manager.

I am grateful for the way our Corporate Marketing & Communications department has grown and gelled over the years, and I look forward to supporting the department teams and their ideas for the future.

Coming Together for Science

ResearchGate and MDPI Partner to Boost the Visibility of Open Access Content through Journal Home


Stefan Tochev (CEO, MDPI) and Sören Hofmayer (Co-Founder and Chief Strategy Officer, ResearchGate) meet in Berlin, Germany to take their ongoing discussion further.

When I assumed the role of CEO at MDPI, my primary focus was to initiate the building of essential partnerships and collaborations within our industry. After all, I am a firm believer in achieving our goals by helping others achieve theirs and focusing on co-opetition wherever there is an opportunity. I first touched on the notion of co-opetition in MDPI Insights: The CEO's Letter #3, particularly when discussing collaborations with Elsevier.

In light of this, Sören Hofmayer (Co-Founder and Chief Strategy Officer at ResearchGate) and I connected recently to continue a discussion that had been ongoing for months. I was quickly brought up to speed and felt there was an opportunity for MDPI journals to pilot the Journal Home service that ResearchGate had launched. This would provide a new way for MDPI to engage with authors and readers and amplify the visibility of our journals.

While I receive many offers and opportunities for discussions with vendors, I am a firm believer that timing is everything, and in this case, the time for us is now. Sören and I met in person during my recent visit to Berlin and decided to proceed with piloting ten MDPI journals with the Journal Home service.

The press release below provides further details.

Press Release: Berlin (Germany) and Basel (Switzerland), 15 November 2023

ResearchGate, the professional network for researchers, and MDPI, the largest open access publisher in the world and a pioneer in open access publishing, today announced a partnership that will see ten of MDPI’s open access journals benefit from an enhanced presence on ResearchGate through its innovative Journal Home offering.  

This new partnership will expand the reach and visibility of MDPI’s participating flagship journals with ResearchGate’s highly relevant community of more than 25 million researchers globally.

Around 210,000 version-of-record articles from these 10 titles will be readily available on ResearchGate, including the full archive material and all new articles as they are published. These journals also benefit from enhanced brand visibility, with dedicated journal profiles, prominent representation on all associated article pages and all relevant touchpoints across the ResearchGate network – keeping the journals top-of-mind with their reader and author audiences. All articles covered by the new partnership will automatically be added to the authors’ publication records in ResearchGate. This not only reduces MDPI authors’ needs for direct management but also offers them valuable insights into the impact of their work, including data about readership and citations.

Closing Thoughts

November is Men’s Health Awareness Month


Stefan Tochev (CEO, MDPI) listening to music as he writes at a coffee shop in Basel, Switzerland.

November is dedicated to raising awareness of various men’s health issues. I have been fortunate to have positive male role models in my life, and I strive to share my experiences with others.

I used to take part in Movember, growing my moustache throughout November to raise awareness and funds and to help “change the face of men’s health.” With male family and friends impacted by physical and mental health issues, I have recently become more interested in men’s overall well-being.

Men often face stigma involving the perceived need always to be strong and have things figured out. Recently, I’ve had meaningful conversations with male friends and colleagues about issues we rarely discuss, and it was a positive experience.

Various factors impact men’s health and well-being, all too easily leading to risky health behaviours including a lack of health awareness, poor health education, and negative, culturally induced, behaviour patterns in our work and personal lives. I hope we can break down these barriers in our work environment.

Healthy men help build healthy families and a healthy society

Men are less likely than women to seek help with their physical and mental health struggles. This is a reminder to prioritize your overall well-being. I hope that as men, we will continue to open up to one another, becoming vulnerable in order to share what we are going through. By sharing and by supporting each other, we can learn and grow together. You are not alone, and when you fall, you can still get up and stand tall.

From one broski to another, you are loved and appreciated. I hope this mindset carries into December and beyond.

Mindfulness

Our content team recently released a handful of articles on mindfulness, a practice that I believe provides a good opportunity for stress release and self-reflection:

Stefan Tochev
Chief Executive Officer
MDPI AG

29 November 2023
Journal of Personalized Medicine | Top 15 Cited Papers on Disease Biomarkers in 2022


We are pleased to invite you to read the following 15 most highly cited papers published on the topic of disease biomarkers in the Journal of Personalized Medicine (JPM, ISSN: 2075-4426) in 2022.

1. “Emerging Biomarkers for Early Detection of Chronic Kidney Disease”
by Maja Mizdrak, Marko Kumrić, Tina Tičinović Kurir and Joško Božić
J. Pers. Med. 2022, 12(4), 548; https://doi.org/10.3390/jpm12040548
Available online: https://www.mdpi.com/2075-4426/12/4/548

2. “Sensory Ion Channel Candidates Inform on the Clinical Course of Pancreatic Cancer and Present Potential Targets for Repurposing of FDA-Approved Agents”
by Wenjie Shi, Chen Li, Thomas Wartmann, Christoph Kahlert, Renfei Du, Aristotelis Perrakis, Thomas Brunner, Roland S. Croner and Ulf D. Kahlert
J. Pers. Med. 2022, 12(3), 478; https://doi.org/10.3390/jpm12030478
Available online: https://www.mdpi.com/2075-4426/12/3/478

3. “Multi-Omics Profiling Approach to Asthma: An Evolving Paradigm”
by Yadu Gautam, Elisabet Johansson and Tesfaye B. Mersha
J. Pers. Med. 2022, 12(1), 66; https://doi.org/10.3390/jpm12010066
Available online: https://www.mdpi.com/2075-4426/12/1/66

4. “Deep Learning-Based Diagnosis of Alzheimer’s Disease”
by Tausifa Jan Saleem, Syed Rameem Zahra, Fan Wu, Ahmed Alwakeel, Mohammed Alwakeel, Fathe Jeribi and Mohammad Hijji
J. Pers. Med. 2022, 12(5), 815; https://doi.org/10.3390/jpm12050815
Available online: https://www.mdpi.com/2075-4426/12/5/815

5. “The Importance of SNPs at miRNA Binding Sites as Biomarkers of Gastric and Colorectal Cancers: A Systematic Review”
by Fatemeh Hajibabaie, Navid Abedpoor, Nazanin Assareh, Mohammad Amin Tabatabaiefar, Laleh Shariati and Ali Zarrabi
J. Pers. Med. 2022, 12(3), 456; https://doi.org/10.3390/jpm12030456
Available online: https://www.mdpi.com/2075-4426/12/3/456

6. “Dysregulated miRNAs as Biomarkers and Therapeutical Targets in Neurodegenerative Diseases”
by Giulia Gentile, Giovanna Morello, Valentina La Cognata, Maria Guarnaccia, Francesca Luisa Conforti and Sebastiano Cavallaro
J. Pers. Med. 2022, 12(5), 770; https://doi.org/10.3390/jpm12050770
Available online: https://www.mdpi.com/2075-4426/12/5/770

7. “Machine Learning-Assisted FTIR Analysis of Circulating Extracellular Vesicles for Cancer Liquid Biopsy”
by Riccardo Di Santo, Maria Vaccaro, Sabrina Romanò, Flavio Di Giacinto, Massimiliano Papi, Gian Ludovico Rapaccini, Marco De Spirito, Luca Miele, Umberto Basile and Gabriele Ciasca
J. Pers. Med. 2022, 12(6), 949; https://doi.org/10.3390/jpm12060949
Available online: https://www.mdpi.com/2075-4426/12/6/949

8. “CDK1 and HSP90AA1 Appear as the Novel Regulatory Genes in Non-Small Cell Lung Cancer: A Bioinformatics Approach”
by Nirjhar Bhattacharyya, Samriddhi Gupta, Shubham Sharma, Aman Soni, Sali Abubaker Bagabir, Malini Bhattacharyya, Atreyee Mukherjee, Atiah H. Almalki, Mustfa F. Alkhanani, Shafiul Haque et al.
J. Pers. Med. 2022, 12(3), 393; https://doi.org/10.3390/jpm12030393
Available online: https://www.mdpi.com/2075-4426/12/3/393

9. “Current Status, Issues and Future Prospects of Personalized Medicine for Each Disease”
by Yuichi Yamamoto, Norihiro Kanayama, Yusuke Nakayama and Nobuko Matsushima
J. Pers. Med. 2022, 12(3), 444; https://doi.org/10.3390/jpm12030444
Available online: https://www.mdpi.com/2075-4426/12/3/444

10. “miR-155: A Potential Biomarker for Predicting Mortality in COVID-19 Patients”
by Reut Kassif-Lerner, Keren Zloto, Nadav Rubin, Keren Asraf, Ram Doolman, Gidi Paret and Yael Nevo-Caspi
J. Pers. Med. 2022, 12(2), 324; https://doi.org/10.3390/jpm12020324
Available online: https://www.mdpi.com/2075-4426/12/2/324

11. “Olfaction Recovery following Dupilumab Is Independent of Nasal Polyp Reduction in CRSwNP”
by Elena Cantone, Eugenio De Corso, Filippo Ricciardiello, Claudio Di Nola, Giusi Grimaldi, Viviana Allocca and Gaetano Motta
J. Pers. Med. 2022, 12(8), 1215; https://doi.org/10.3390/jpm12081215
Available online: https://www.mdpi.com/2075-4426/12/8/1215

12. “Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer”
by Michael J. Duffy and John Crown
J. Pers. Med. 2022, 12(1), 99; https://doi.org/10.3390/jpm12010099
Available online: https://www.mdpi.com/2075-4426/12/1/99

13. “Theratyping of the Rare CFTR Variants E193K and R334W in Rectal Organoid-Derived Epithelial Monolayers”
by Fabiana Ciciriello, Marcel J. C. Bijvelds, Federico Alghisi, Kelly F. Meijsen, Luca Cristiani, Claudio Sorio, Paola Melotti, Alessandro G. Fiocchi, Vincenzina Lucidi and Hugo R. De Jonge
J. Pers. Med. 2022, 12(4), 632; https://doi.org/10.3390/jpm12040632
Available online: https://www.mdpi.com/2075-4426/12/4/632

14. “Personalized Management of Myocarditis and Inflammatory Cardiomyopathy in Clinical Practice”
by Agata Tymińska, Krzysztof Ozierański, Aleksandra Skwarek, Agnieszka Kapłon-Cieślicka, Anna Baritussio, Marcin Grabowski, Renzo Marcolongo and Alida LP Caforio
J. Pers. Med. 2022, 12(2), 183; https://doi.org/10.3390/jpm12020183
Available online: https://www.mdpi.com/2075-4426/12/2/183

15. “From Skin Barrier Dysfunction to Systemic Impact of Atopic Dermatitis: Implications for a Precision Approach in Dermocosmetics and Medicine”
by Laura Maintz, Thomas Bieber, Helen D. Simpson and Anne-Laure Demessant-Flavigny
J. Pers. Med. 2022, 12(6), 893; https://doi.org/10.3390/jpm12060893
Available online: https://www.mdpi.com/2075-4426/12/6/893

21 November 2023
769 Editorial Board Members of MDPI Journals Achieve Highly Cited Researcher Recognition in 2023


We extend our sincere congratulations to the 769 Editorial Board Members of our journals – from 40 different countries/territories – who have been recognized as Highly Cited Researchers for the year 2023 by Clarivate. They are being recognized for their high-quality scientific research achievements and outstanding contributions to their professional fields, as indicated by Web of Science data.

Clarivate's annual list of Highly Cited ResearchersTM identifies the most highly cited scientists for the past decade who stand out for their significant and broad influence in various scientific and social science domains. Their impactful papers are among the top 1 per cent in the citation distribution of one or more of 21 fields analyzed in the "Essential Science Indicators", distinguishing them as hugely influential among their peers.

This year, 7,125 Highly Cited Researcher 2023 designations were issued to 6,849 individuals from 67 countries, representing just 1 in 1,000 researchers worldwide.

This means that these researchers have demonstrated an incredible level of significant and broad influence in their chosen field or fields over the last decade. They represent a small fraction of the researcher population whose contributions disproportionately push the boundaries of knowledge, enhancing global well-being, sustainability, and security.

Congratulations to the scholars for their noteworthy achievement – we are honored to have them on board with our journals!


Abate, Antonio
Aguilera, Ruth V.
Ahmed, Warish
Ahn, Myung-Ju
An, Qiaoshi
Anasori, Babak
Andersson, Dan I.
Angeletti, Silvia
Annabi, Nasim
Antinori, Spinello
Ariga, Katsuhiko
Asa, Sylvia L.
Astruc, Didier
Atala, Anthony
Atanasov, Atanas G.
Balsamo, Gianpaolo
Bandodkar, Amay J.
Banks, William A.
Bao, Yan-Ping
Barba, Francisco J.
Barnes, Peter J.
Barnholtz-Sloan, Jill S.
Barrow, Colin J.
Bashir, Ali Kashif
Basit, Abdul W.
Bassetti, Matteo
Batley, Jacqueline
Battino, Maurizio
Behnood, Ali
Benediktsson, Jon Atli
Biondi, Antonio
Bjarnsholt, Thomas
Blaschke, Thomas
Blay, Jean-Yves
Blumwald, Eduardo
Blunt, John W.
Boczkaj, Grzegorz
Bogers, Marcel
Bonomo, Robert A.
Boyd, Robert W.
Boyer, Cyrille
Braeckmans, Kevin
Bragazzi, Nicola Luigi
Bu, Wenbo
Bursać Kovačević, Danijela
Bush, Ashley I.
Byrd, John C.
Cabeza, Luisa F.
Cai, Xingjuan
Cambria, Erik
Cao, Guozhong
Cao, Xingzhong
Capasso, Raffaele
Carvalho, Andre F.
Casper, Jonathan
Castellanos-Gomez, Andres
Cavalli, Giacomo
Chai, Siang-Piao
Chan, Jasper Fuk-Woo
Chan, Timothy A.
Chang, Chih-Hao
Chang, Guoqing
Chao, Dongliang
Chen, Bo
Chen, Chaoji
Chen, Fahu
Chen, Gang
Chen, Jianmin
Chen, Jun
Chen, Jun
Chen, Jun
Chen, Lidong
Chen, Lingxin
Chen, Min
Chen, Mou
Chen, Peng
Chen, Qian
Chen, Qianwang
Chen, Shaowei
Chen, Shuangming
Chen, Wei
Chen, Xiaobo
Chen, Yimin
Chen, Yu
Chen, Yulin
Chen, Zhong
Chen, Zonghai
Cheng, Gong
Cheng, Huanyu
Cheng, Laifei
Cheng, Qiang
Chew, Kit Wayne
Chiclana, Francisco
Choi, Wonyong
Choi, Young Hae
Chowdhary, Anuradha
Cichocki, Andrzej
Clevers, Hans
Coops, Nicholas C.
Cortes, Javier
Cortes, Jorge
Costanza, Robert
Creutzig, Felix
Crommie, Michael F.
Cuadrado, Antonio
Cui, Haiying
Cui, Yi
Curigliano, Giuseppe
Dai, Sheng
Dai, Shifeng
Daiber, Andreas
Davies, Michael J.
Davis, Thomas P.
Dawson, Ted M.
de la Fuente-Nunez, Cesar
Delord, Jean-Pierre
Demaria, Marco
Deng, Xiangzheng
Desneux, Nicolas
Dikic, Ivan
Dimopoulos, Meletios-Athanasios
Ding, Aijun
Ding, Jianxun
Dokmeci, Mehmet Remzi
Dolgui, Alexandre
Dong, Chung-Li
Dou, Shi Xue
Dragicevic, Tomislav
Du, Bo
Du, Qian
Du, Yonghua
Duan, Xidong
Dufresne, Alain
Dummer, Reinhard
Edwards, David
Elaissari, Abdelhamid
ElMasry, Gamal
Enjuanes, Luis
Fabbro, Doriano
Facchetti, Antonio
Fan, Junliang
Fan, Kelong
Fan, Xiulin
Fan, Zhanxi
Fang, Baizeng
Fang, Chuanglin
Fang, Yongjin
Fasano, Alessio
Feng, Liangzhu
Feng, Xuning
Fensholt, Rasmus
Ferdinandy, Péter
Fernandez-Lafuente, Roberto
Filippi, Massimo
Flavian, Carlos
Fortino, Giancarlo
Fowler, Michael
Franceschi, Claudio
Frattini, Federico
Friston, Karl J.
Fu, Gengtao
Gai, Francesco
Gaisford, Simon
Galanakis, Charis M.
Galluzzi, Lorenzo
Galvano, Fabio
Gan, Ren-You
Gao, Feng
Gao, Huijun
Gao, Huile
Gao, Peng
Gao, Wei
Garbe, Claus
Garg, Abhishek D.
Gasbarrini, Antonio
Gastaldelli, Amalia
Gautier, Emmanuel L.
Genevet, Patrice
Geng, Yong
Gerdts, Gunnar
Geschwind, Daniel H.
Ghaffari, Roozbeh
Ghamisi, Pedram
Giacobbe, Daniele Roberto
Giampieri, Francesca
Gillies, Robert J.
Godos, Justyna
Gogotsi, Yury
Golding, Nick
Gong, Jinlong
Gong, Peng
Gong, Yongji
Govindan, Kannan
Gozal, David
Grancini, Giulia
Grant, William B.
Graus, Francesc
Green, Douglas R.
Grosso, Giuseppe
Gu, Meng
Gu, Zhanjun
Guan, Cao
Gueimonde, Miguel
Gui, Guan
Guigo, Roderic
Guo, Hengyu
Guo, Jianping
Guo, Lin
Guo, Song
Guo, Yan
Guo, Zaiping
Gupta, Rangan
Gutzmer, Ralf
Haase, Dagmar
Hagger, Martin S.
Hall, C. Michael
Han, Fudong
Han, Heesup
Hanes, Justin
Hartung, Hans-Peter
He, Bao-Jie  
He, Debiao
He, Hongwen
He, Jiaqing
He, Jie
He, Jr-Hau
He, Qiong
He, Xiangming
He, Xijun
He, Zhili
Heneka, Michael T.
Herrera, Francisco
Herrera-Estrella, Luis
Herrera-Viedma, Enrique
Hetz, Claudio
Holick, Michael F.
Hong, Danfeng
Hong, Xuechuan
Hsueh, Po-Ren
Hu, Bin
Hu, Enyuan
Hu, Jin-Song
Hu, Weida
Hu, Wenbin
Hu, Xiaosong
Huang, Baibiao
Huang, Hongwei
Huang, Jianliang
Huang, Jianping
Huang, Peng
Huang, Xin
Hubacek, Klaus
Hussain, Saddam
Italiano, Antoine
Iwata, Hiroji
Jaeschke, Hartmut
Jain, Atul

Jaiswal, Amit K.
Jankovic, Joseph
Janssens, Ivan A.
Jelezko, Fedor
Jeon, Byong-Hun
Ji, Guangbin
Ji, Qiang
Ji, Wei
Ji, Xiaobo
Ji, Xiaoyuan
Jiang, Bin
Jiang, Hong
Jiang, Junjun
Jiang, Lianzhou
Jiang, Qing
Jiang, Shibo
Jiang, Yuyan
Jiang, Zhongyi
Jiao, Licheng
Jin, Shi
Jin, Zhong
Kalantar-zadeh, Kourosh
Kamal, Mohammad Amjad
Kaner, Richard B.
Kaneti, Yusuf Valentino
Kang, Zhenhui
Karagiannidis, George K.
Karniadakis, George Em
Karp, Peter D.
Kataoka, Kazunori
Katritch, Vsevolod
Kawi, Sibudjing
Kepp, Oliver
Khademhosseini, Ali
Khan, Nafees A.
Kiessling, Fabian
Kildishev, Alexander V.
Kim, Haegyeom
Kim, Jeonghun
Kim, Jin-Hoi
Kim, Jong Seung
Kim, Ki-Hyun
Kirkwood, John M.
Kivshar, Yuri
Klenk, Hans-Peter
Ko, Wen-Chien
Kong, Baohua
Kontoyiannis, Dimitrios P.
Koonin, Eugene V.
Kroemer, Guido
Kuang, Dai-Bin
Kudo, Masatoshi
Kuhn, Jens H.
Kumar, Prashant
Kumar, Sudhir
Kurths, Juergen
Kurzrock, Razelle
Kuzyakov, Yakov
Kyrpides, Nikos C.
La Vecchia, Carlo
Lai, Yuekun
Lan, Ke
Lancellotti, Patrizio
Landi, Francesco
Lavie, Carl J.
Laxminarayan, Ramanan
Lee, Chengkuo
Lee, Jechan
Lee, Jin-Wook
Lee, Pooi See
Lee, Sang Soo
Lehmann, Johannes
Lei, Yaguo
Li, Bin
Li, Chunzhong
Li, Dongsheng
Li, Feng
Li, Hai
Li, Heng
Li, Hongyi
Li, Hui
Li, Jinghong
Li, Jun
Li, Li
Li, Linlin
Li, Neng
Li, Ning
Li, Shuai
Li, Shutao
Li, Wei
Li, Wentao
Li, Xiang
Li, Xuecao
Li, Xuelong
Li, Yat
Li, Yurui
Li, Zhijun
Liang, Chao
Liang, Shuquan
Liaw, Peter K.
Lin, Jun
Lin, Yuehe
Lippi, Giuseppe
Lister, Ryan
Liu, Chengmei
Liu, Gang
Liu, Hong
Liu, Hui
Liu, Jian
Liu, Jinyan
Liu, Jun
Liu, Meilin
Liu, Pan
Liu, Wei
Liu, Xianhu
Liu, Xiaoping
Liu, Xuejun
Liu, Yang
Liu, Yu
Liu, Yuan
Lonardo, Amedeo
Long, Hualou
Long, Ying
Lu, Bingan
Lu, Junling
Lu, Lu
Lu, Nanshu
Lu, Rongxing
Lucey, Brian
Lucieer, Arko
Lugato, Emanuele
Lund, Henrik
Luo, Yangchao
Luo, Yi
Luo, Zisheng
Lv, Wei
Lyons, Timothy W.
Ma, Haile
Ma, Jianmin
Ma, Jun
Ma, Tianyi
Ma, Wei
Ma, Yanming
Madabhushi, Anant
Mahmoudi, Morteza
Mai, Liqiang
Mai, Wenjie
Makridakis, Spyros
Mandala, Mario
Mantovani, Alberto
Mao, Jianfeng
Mao, Like
Mardani, Abbas
Mathivanan, Suresh
Matyjaszewski, Krzysztof
McCabe, Matthew F.
McCauley, Darren
McClements, David Julian
Mei, Lin
Melenhorst, Jan Joseph
Melero, Ignacio
Meyerholz, David K.
Van Mierlo, Joeri
Miroshnichenko, Andrey E.
Mittler, Ron
Mu, Shichun
Mubarak, Mohammad S.
Mueller, Lukas A.
Muhammad, Khan
Mumtaz, Shahid
Munekata, Paulo Eduardo Sichetti
Nakagawa, Shinichi
Nauen, Ralf
Newman, David J.
Niaura, Raymond S.
Nidheesh, P. V.
Niu, Ben
Nussinov, Ruth
O'Connor, David
Odintsov, Sergei D.
Omri, Anis
Orsini, Nicola
Ostrikov, Kostya (Ken)
Oswald, Isabelle P.
Oudard, Stephane
Ouyang, Minggao
Ozcan, Aydogan
Pan, Anlian
Pan, Anqiang
Pan, Caofeng
Pan, Genxing
Pan, Likun
Pan, Quan-Ke
Pan, Xiaoqing
Pandolfi, Pier Paolo
Parati, Gianfranco
Pateiro, Mirian
Peng, Qiang
Peng, Qing
Peng, Shushi
Perc, Matjaz
Perlin, David S.
Perlman, Stanley
Petruzzelli, Antonio Messeni
Pitt, Bertram
Pöhlmann, Stefan
Polasky, Stephen
Pommier, Yves
Poor, H. Vincent
Potenza, Marc N.
Preat, Veronique
Prinsep, Michele R.
Pu, Kanyi
Putnik, Predrag
Qin, Yuanwei
Qiu, Jieshan
Qu, Xiaogang
Ragauskas, Arthur J.
Ramakrishna, Seeram
Ramkissoon, Haywantee
Ran, Jingrun
Rao, Zhonghao
Recio, Isidra
Ren, Jinsong
Rengel, Zed
Rho, Junsuk
Riahi, Keywan
Ribeiro-Soriano, Domingo
Richardson, Paul G.
Robert, Caroline
Rocca, Maria A.
Rodriguez-Manas, Leocadio
Rojas, Orlando J.
Rojo, Teofilo
Roubaud, David
Saad, Fred
Saad, Walid
Sadorsky, Perry
Saliba, Michael
Sander, Chris
Sangaiah, Arun Kumar
Santamouris, Mattheos
Santoro, Gabriele
Scaldaferri, Franco
Schatzberg, Alan F.
Schwab, Matthias
Schweizer, Frank
Scolyer, Richard A.
Scott, Daniel
Serruys, Patrick W.
Setzer, William N.
Shahzad, Babar
Shao, Shuai
Shao, Zongping
Shen, Guozhen
Shen, Liyin

Shen, Zexiang
Shi, Peng
Shi, Yi
Siano, Pierluigi
Simões, Manuel
Sing, Swee Leong
Singh, Vijay P.
Smagghe, Guy
Smith, Lee
Soffietti, Riccardo
Song, Houbing
Song, Jibin
Song, Yu
Sood, Anil K.
Souto, Eliana B.
Stadler, Marc
Stanley, H. Eugene
Stephanopoulos, Gregory
Sternberg, Cora N.
Stoumpos, Constantinos C.
Stunnenberg, Hendrik G.
Su, Shiliang
Sun, Baoguo
Sun, Cuixia
Sun, Fengchun
Sun, Hongqi
Sun, Jie
Sun, Lijun
Sun, Litao
Sun, Runcang
Sun, Yanjuan
Sun, Zaicheng
Sun, Zhipei
Sureda, Antoni
Svenning, Jens-Christian
Tan, Chaoliang
Tan, Weihong
Tang, Chuan-He
Tang, Chuyang
Tang, Dianping
Tang, Yongbing
Tanzi, Rudolph E.
Terpos, Evangelos
Teschendorff, Andrew E.
Tian, He
Timsit, Jean-Francois
Tiwari, Aviral Kumar
Tohge, Takayuki
Tousoulis, Dimitris
Tran, Lam-Son Phan
Tress, Wolfgang
Trivedi, Pankaj
Tsao, Rong
Tully, Mark A.
Tung, Chen-Ho
Van der Bruggen, Bart
Vandenbroucke, Roosmarijn E.
Vangronsveld, Jaco
Varsani, Arvind
Vatanen, Tommi
Verbeke, Kristin
Vermote, Eric
Verpoorte, Robert
Vieta, Eduard
Vincent, Jean-Louis
Vita, Antonio
Wan, Jiafu
Wan, Shaohua
Wanek, Wolfgang
Wang, Bin
Wang, Bo
Wang, Chao
Wang, Chuanyi
Wang, Chunsheng
Wang, Dan
Wang, Feng
Wang, Gongming
Wang, Guoxiu
Wang, Haihui
Wang, Hao
Wang, Huanqing
Wang, Huanting
Wang, Hui
Wang, Jian
Wang, Jie
Wang, Jing
Wang, John
Wang, Joseph
Wang, Lianzhou
Wang, Lihui
Wang, Meng
Wang, Peng
Wang, Pengfei
Wang, Qi
Wang, Qi
Wang, Qiang
Wang, Qilin
Wang, Qin
Wang, Qing
Wang, Shaojian
Wang, Sibo
Wang, Tao
Wang, Ying
Wang, Yong
Wang, Zhen
Wang, Zhong Lin
Wang, Zhongrui
Wang, Zifa
Wang, Zuankai
Wei, Haotong
Wei, Leyi
Wei, Zhixiang
Wei, Zhongbao
Weissleder, Ralph
Weitschies, Werner
Wen, Guanghui
Wesemael, Bas van
Willerslev, Eske
Witlox, Frank
Wu, Haijun
Wu, Hao Bin
Wu, Hui
Wu, Jun
Wu, Qinglin
Wu, Shuilin
Wu, Xiaojun
Wu, Yongzhen
Wu, Yuping
Wu, Zheng-Guang
Wu, Zhong-Shuai
Xia, Jianguo (Jeff)
Xia, Meimei
Xia, Xinhui
Xia, Yongyao
Xia, Zhiguo
Xiang, Quanjun
Xiao, Fuyuan
Xiao, Jie
Xin, Sen
Xing, Baoshan
Xing, Wei
Xiong, Rui
Xu, Hui
Xu, Li Da
Xu, Ping
Xu, Yi-Jun
Xu, Zhenjiang Zech
Yan, Chong
Yan, He
Yan, Huaicheng
Yan, Kai
Yan, Ruqiang
Yang, Bing
Yang, Chenguang
Yang, Hongshun
Yang, Hui
Yang, Jian
Yang, Jianping
Yang, Jie
Yang, Jun
Yang, Kai
Yang, Shihe
Yang, Xiaofeng
Yang, Xinsong
Yang, Yun-Gui
Yao, Yonggang
Yigitcanlar, Tan
Yin, Shen
Yin, Shou-Wei
Yin, Yulong
Yin, Zongyou
Yokoya, Naoto
Young, Allan H.
Yu, Guihua
Yu, Jun
Yu, Le
Yu, Minghao
Yu, Shu-Hong
Yu, Wei
Yu, Wenwu
Yuan, Qiangqiang
Yuan, Yifei
Yuan, Yuan
Yuen, Chau
Zeadally, Sherali
Zhai, Tianyou
Zhang, Bing
Zhang, Dengsong
Zhang, Fan
Zhang, Fusuo
Zhang, Guangyu
Zhang, Guowen
Zhang, Hengjie
Zhang, Hongjie
Zhang, Hui
Zhang, Lai-Chang
Zhang, Lefei
Zhang, Lei
Zhang, Liangpei
Zhang, Lijun
Zhang, Min
Zhang, Peng
Zhang, Qiang
Zhang, Qiaobao
Zhang, Qichun
Zhang, Shicheng
Zhang, Shujun
Zhang, Tierui
Zhang, Wei
Zhang, Weili
Zhang, Xian-Ming
Zhang, Xiaodong
Zhang, Xiaogang
Zhang, Xiaoling
Zhang, Yang
Zhang, Yaobin
Zhang, Yi
Zhang, Yi-Zhou
Zhang, Yong
Zhang, Yu Shrike
Zhang, Yue-Jun
Zhang, Yuelin
Zhang, Zheng
Zhang, Zhicheng
Zhang, Zhien
Zhao, Guochun
Zhao, Jie
Zhao, Li-Dong
Zhao, Qing
Zhao, Yi
Zheng, Hao
Zheng, Weitao
Zheng, Yufeng
Zhong, Cheng
Zhou, Jie
Zhou, Jizhong
Zhou, Kun
Zhou, Liang
Zhou, Peng
Zhou, Qi
Zhou, Wei
Zhou, Weiqi
Zhu, Chengzhou
Zhu, Hongwei
Zhu, Junfa
Zhu, Jun-Jie
Zhu, Lei
Zhu, Mingshan
Zhu, Quanxin
Zhu, Yi
Zhu, Yongfa
Zhu, Zhe
Zhuang, Xiaodong
Zou, Quan
Zou, Ruqiang
Zuo, Chao

14 November 2023
Journal of Personalized Medicine | Top 15 Cited Papers on Precision Oncology in 2022


We are pleased to invite you to read the highly cited papers in 2022 from the Journal of Personalized Medicine (JPM, ISSN: 2075-4426), on the topic of precision oncology. The paper list is as follows:

1. “Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems”
by Stefano Marletta, Nicola Fusco, Enrico Munari, Claudio Luchini, Alessia Cimadamore, Matteo Brunelli, Giulia Querzoli, Maurizio Martini, Elena Vigliar, Romano Colombari et al.
J. Pers. Med. 2022, 12(7), 1073; https://doi.org/10.3390/jpm12071073
Available online: https://www.mdpi.com/2075-4426/12/7/1073

2. “Sensory Ion Channel Candidates Inform on the Clinical Course of Pancreatic Cancer and Present Potential Targets for Repurposing of FDA-Approved Agents”
by Wenjie Shi, Chen Li, Thomas Wartmann, Christoph Kahlert, Renfei Du, Aristotelis Perrakis, Thomas Brunner, Roland S. Croner and Ulf D. Kahlert
J. Pers. Med. 2022, 12(3), 478; https://doi.org/10.3390/jpm12030478
Available online: https://www.mdpi.com/2075-4426/12/3/478

3. “Identification of Early Esophageal Cancer by Semantic Segmentation”
by Yu-Jen Fang, Arvind Mukundan, Yu-Ming Tsao, Chien-Wei Huang and Hsiang-Chen Wang
J. Pers. Med. 2022, 12(8), 1204; https://doi.org/10.3390/jpm12081204
Available online: https://www.mdpi.com/2075-4426/12/8/1204

4. “Towards Machine Learning-Aided Lung Cancer Clinical Routines: Approaches and Open Challenges”
by Francisco Silva, Tania Pereira, Inês Neves, Joana Morgado, Cláudia Freitas, Mafalda Malafaia, Joana Sousa, João Fonseca, Eduardo Negrão, Beatriz Flor de Lima et al.
J. Pers. Med. 2022, 12(3), 480; https://doi.org/10.3390/jpm12030480
Available online: https://www.mdpi.com/2075-4426/12/3/480

5. “Design and Development of an Intelligent Clinical Decision Support System Applied to the Evaluation of Breast Cancer Risk”
by Manuel Casal-Guisande, Alberto Comesaña-Campos, Inês Dutra, Jorge Cerqueiro-Pequeño and José-Benito Bouza-Rodríguez
J. Pers. Med. 2022, 12(2), 169; https://doi.org/10.3390/jpm12020169
Available online: https://www.mdpi.com/2075-4426/12/2/169

6. “Machine Learning-Assisted FTIR Analysis of Circulating Extracellular Vesicles for Cancer Liquid Biopsy”
by Riccardo Di Santo, Maria Vaccaro, Sabrina Romanò, Flavio Di Giacinto, Massimiliano Papi, Gian Ludovico Rapaccini, Marco De Spirito, Luca Miele, Umberto Basile and Gabriele Ciasca
J. Pers. Med. 2022, 12(6), 949; https://doi.org/10.3390/jpm12060949
Available online: https://www.mdpi.com/2075-4426/12/6/949

7. “CDK1 and HSP90AA1 Appear as the Novel Regulatory Genes in Non-Small Cell Lung Cancer: A Bioinformatics Approach”
by Nirjhar Bhattacharyya, Samriddhi Gupta, Shubham Sharma, Aman Soni, Sali Abubaker Bagabir, Malini Bhattacharyya, Atreyee Mukherjee, Atiah H. Almalki, Mustfa F. Alkhanani, Shafiul Haqu et al.
J. Pers. Med. 2022, 12(3), 393; https://doi.org/10.3390/jpm12030393
Available online: https://www.mdpi.com/2075-4426/12/3/393

8. ”Construction of a miRNA-Based Nomogram Model to Predict the Prognosis of Endometrial Cancer”
by Leyi Ni, Chengyun Tang, Yuning Wang, Jiaming Wan, Morgan G. Charles, Zilong Zhang, Chen Li, Ruijie Zeng, Yiyao Jin, Penghao Song et al.
J. Pers. Med. 2022, 12(7), 1154; https://doi.org/10.3390/jpm12071154
Available online: https://www.mdpi.com/2075-4426/12/7/1154

9. “Explainable Artificial Intelligence for Prediction of Complete Surgical Cytoreduction in Advanced-Stage Epithelial Ovarian Cancer”
by Alexandros Laios, Evangelos Kalampokis, Racheal Johnson, Amudha Thangavelu, Constantine Tarabanis, David Nugent and Diederick De Jong
J. Pers. Med. 2022, 12(4), 607; https://doi.org/10.3390/jpm12040607
Available online: https://www.mdpi.com/2075-4426/12/4/607

10. “Thyroid Diseases and Breast Cancer”
by Enke Baldini, Augusto Lauro, Domenico Tripodi, Daniele Pironi, Maria Ida Amabile, Iulia Catalina Ferent, Eleonora Lori, Federica Gagliardi, Maria Irene Bellini, Flavio Forte et al.
J. Pers. Med. 2022, 12(2), 156; https://doi.org/10.3390/jpm12020156
Available online: https://www.mdpi.com/2075-4426/12/2/156

11. “Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer”
by Michael J. Duffy and John Crown
J. Pers. Med. 2022, 12(1), 99; https://doi.org/10.3390/jpm12010099
Available online: https://www.mdpi.com/2075-4426/12/1/99

12. “CD24: A Novel Target for Cancer Immunotherapy”
by Emmanouil Panagiotou, Nikolaos K. Syrigos, Andriani Charpidou, Elias Kotteas and Ioannis A. Vathiotis
J. Pers. Med. 2022, 12(8), 1235; https://doi.org/10.3390/jpm12081235
Available online: https://www.mdpi.com/2075-4426/12/8/1235

13. “Diffuse Intrinsic Pontine Glioma: Molecular Landscape, Evolving Treatment Strategies and Emerging Clinical Trials”
by Sudarshawn Damodharan, Montserrat Lara-Velazquez, Brooke Carmen Williamsen, Jeffrey Helgager and Mahua Dey
J. Pers. Med. 2022, 12(5), 840; https://doi.org/10.3390/jpm12050840
Available online: https://www.mdpi.com/2075-4426/12/5/840

14. “Multi-Class Classification of Breast Cancer Using 6B-Net with Deep Feature Fusion and Selection Method”
by Muhammad Junaid Umer, Muhammad Sharif, Seifedine Kadry and Abdullah Alharbi
J. Pers. Med. 2022, 12(5), 683; https://doi.org/10.3390/jpm12050683
Available online: https://www.mdpi.com/2075-4426/12/5/683

15. “Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective”
by Danijel Galun, Dragana Mijac, Aleksandar Filipovic, Aleksandar Bogdanovic, Marko Zivanovic and Dragan Masulovic
J. Pers. Med. 2022, 12(2), 149; https://doi.org/10.3390/jpm12020149
Available online: https://www.mdpi.com/2075-4426/12/2/149

1 November 2023
MDPI Insights: The CEO's Letter #5 - OA Week, UK, and Strategy

Welcome to the MDPI Insights: The CEO's Letter.

In these monthly letters, I will showcase two key aspects of our work at MDPI: our commitment to empowering researchers and our determination to facilitating open scientific exchange.


Opening Thoughts

Open Access Week 2023 – the Global Drive to Open Continues

As the world's largest open-access (OA) publisher, we believe that unrestricted access to research findings is the cornerstone of transparency, efficiency, and quality control across scientific disciplines. At MDPI, we provide free, immediate access to scientific papers, empowering scientists to examine, validate, replicate, and build upon existing results. This minimizes redundancy, optimizes resources, and fosters innovative approaches.

International OA Week, held from 23 to 29 October 2023, provided a unique opportunity to link the global movement toward open sharing and open science with the progress of policy changes at the local level. Our mission, during OA Week and all the year round, is to offer educational resources highlighting the benefits of open-access publishing. The MDPI Blog is a valuable resource for information on open access and open science.

Core principles of OA publishing

Accessibility, transparency, and collaboration are core principles of OA publishing. OA aims to break down barriers that have traditionally restricted research access, ensuring that knowledge is available to all, regardless of financial situation or institutional affiliations. Our commitment to diverse pathways for OA publishing worldwide includes discounts for researchers. You can learn more about how MDPI supports scientific communities here.

One of the key strengths of OA publishing is its ability to facilitate interdisciplinary research. By removing paywalls and promoting knowledge-sharing across disciplines, OA encourages collaboration and innovation. Researchers from various fields can access and build upon each others’ work, fostering a holistic approach to addressing complex global challenges.

OA holds the potential to democratize knowledge, advance science, and drive positive societal change.

Policy driving change

Governments, institutions, and funding agencies have recognized the transformative potential of OA and have implemented policies to promote it. These policies often require publicly funded research to be made openly accessible, accelerating the growth of OA repositories and journals. Check out our spotlights on OA policies in the USEU and China

OA publishing is continuously evolving, with community-driven models and technologies shaping its future. Initiatives such as “Plan S” and “cOAlition S” promote OA publishing from the perspective of national funders, requiring grantees to publish their research openly. A new policy announced by the US administration last year mandates that, with effect from January 2026, all US federally funded research should be freely and immediately available after publication.

Additionally, preprint servers such as MDPI's Preprints.org, which allow researchers to share their findings before formal peer review, have gained popularity, enhancing the speed at which new knowledge is disseminated. The rise of blockchain technology is also being explored to ensure transparency and authenticity in scholarly publishing.

For more than two decades, OA publishing has been revolutionizing academic publishing by promoting accessibility, transparency, and collaboration. Its support for interdisciplinary research, evolving policies, and innovative practices all contribute to its growing influence in the global research community. As OA continues to expand, it holds the potential to democratize knowledge, advance science, and drive positive societal change.

MDPI is proud to lead the transition to open access.

Read more:

Impactful Research

Spotlight on Smart Cities

Smart cities will serve as a cornerstone for future human development. Their implementation will help us tackle many of the significant challenges we are facing – climate change, ageing populations, waste management, public safety, travel, and so on. Recognising the importance of this multifaceted field, MDPI launched the inaugural issue of Smart Cities in 2018 to provide an advanced forum for research into smart technology and society. Here we take a look at how this journal has developed, and its impact in this exciting field.

As at 30 October, 2023, Smart Cities has published 421 papers and has an Impact Factor of 6.4. It also has a CiteScore of 8.5, and more than one quarter of its published papers – 124 – have been cited 10 times or more.

Highly cited papers in Smart Cities

Below are several highly cited papers recently published in Smart Cities. Citation metrics are current as at 31 October 2023.

1. “Introducing the “15-Minute City”: Sustainability, Resilience and Place Identity in Future Post-Pandemic Cities
Authors: Carlos Moreno, Zaheer Allam, Didier Chabaud, Catherine Gall and Florent Pratlong
Smart Cities 2021, 4(1), 93-111; https://doi.org/10.3390/smartcities4010006
Citations: Crossref (338), Scopus (366), Web of Science (270), Google Scholar (710)
The paper discusses the socio-economic impacts of the COVID-19 on cities, including increasing inequalities and rising unemployment. It introduces the concept of the "15-Minute City," a form of "chrono-urbanism," as a response to the challenges posed by the pandemic.

2. “A Review on Electric Vehicles: Technologies and Challenges
Authors: Julio A. Sanguesa, Vicente Torres-Sanz, Piedad Garrido, Francisco J. Martinez and Johann M. Marquez-Barja
Smart Cities 2021, 4(1), 372-404; https://doi.org/10.3390/smartcities4010022
Citations: Crossref (359), Scopus (363), Web of Science (268), Google Scholar (558)
This paper provides an overview of the progress in Electric Vehicles (EVs), focusing on battery technology, charging methods, and emerging research challenges. It also analyzes the global EV market and its future outlook.

3. “IoT in Smart Cities: A Survey of Technologies, Practices and Challenges
Authors: Abbas Shah Syed, Daniel Sierra-Sosa, Anup Kumar and Adel Elmaghraby
Smart Cities 2021, 4(2), 429-475; https://doi.org/10.3390/smartcities4020024
Citations: Crossref (121), Scopus (151), Web of Science (91), Google Scholar (215)
This paper gives an overview of the Internet of Things (IoT) in the context of Smart Cities, discussing the fundamental components, technologies, architectures, networking technologies, and artificial algorithms that underpin IoT-based Smart City systems.

4. “Artificial Intelligence Techniques in Smart Grid: A Survey
Authors: Olufemi A. Omitaomu and Haoran Niu
Smart Cities 2021, 4(2), 548-568; https://doi.org/10.3390/smartcities4020029
Citations: Crossref (76), Scopus (94), Web of Science (57), Google Scholar (120)
This survey paper reviews the utilization of artificial intelligence (AI) techniques in the context of the smart grid. It covers various applications of AI in load forecasting, power grid stability assessment, fault detection, and security issues in the smart grid and power systems.

5. “The Metaverse as a Virtual Form of Smart Cities: Opportunities and Challenges for Environmental, Economic, and Social Sustainability in Urban Futures
Authors: Zaheer Allam, Ayyoob Sharifi, Simon Elias Bibri, David Sydney Jones and John Krogstie
Smart Cities 2022, 5(3), 771-801; https://doi.org/10.3390/smartcities5030040
Citations: Crossref (72), Scopus (75), Web of Science (43), Google Scholar (176)
This paper discusses the concept of the Metaverse, a virtual world introduced by Meta (formerly Facebook), and its potential impact on urban life. It explores how emerging technologies such as AI, Big Data, IoT, and Digital Twins could reshape urban design and services in the context of the Metaverse.

Testimonial

“It was indeed a great and pleasant experience with MDPI regarding our recent publication. The submission process was very straightforward and less time-consuming than the norm. The review process was very fast compared to many other open access journals, which is praiseworthy. The support from the Editorial Office during the revision process was highly useful as well. We look forward to publishing with MDPI in the future, and I will most definitely recommend MDPI to my colleagues and collaborators. – Dr. Luís Rosa, University of Minho

Article in Smart Cities: Mobile Networks and Internet of Things Infrastructures to Characterize Smart Human Mobility

Inside MDPI

MDPI Manchester office, UK Visit


Allie Shi (Editorial Director, MDPI), Stefan Tochev (CEO, MDPI), Jamie Anderson (Manchester Office Manager, MDPI), Michael O’Sullivan (Senior Scientific Officer, MDPI), Hushneara Akhtar, and Becky Castellon (IOAP Team Lead, MDPI), dining out in Manchester, UK.

In October, I visited MDPI’s new office in Manchester. During the visit, I connected with our English Editing (EE) managers, Scientific Officer, members of the Editorial team, the Marketing team, and IOAP Team Lead.

Our Manchester office focuses primarily on EE services and provides local support for the UK market. Additionally, we regularly visit Editorial Board members and participate in local conferences.

I would like to thank Jamie Anderson, Manchester Office Manager, and her team, for their deep commitment to our Manchester staff and to MDPI’s impact on the UK market.

The UK by numbers

The UK is a hub for the world’s top universities, making it a key market for MDPI and the publishing world in general. It is home to two of the top-five-ranked universities globally, 11 in the top 100, and 15 in the top 200.

As a result, the UK plays a key role in MDPI’s global market. As at October 2023, it ranks as the seventh-largest contributor to the total number of papers published by MDPI. We have 3,500 Editorial Board members affiliated with UK institutions, including 34 serving as Editors-in-Chief (EiCs). Our commitment to collaboration with institutions is evident in the UK, where we have successfully established some 60 Institutional Open Access Program (IOAP) agreements with esteemed institutions, such as the University of Oxford, the University of Cambridge, Imperial College London, the University of Edinburgh, and more.

According to InCites Dataset + ESCI for the period 2018–2022, as at October 2023, nearly 65% of UK papers are now published as OA. Just over 10% of total OA publications are by UK authors. UK papers are known for their high quality, with an average of 11 citations per paper. Furthermore, 2.16% of UK papers are in the top 1% of cited papers, and 14.61% are in the top 10% of cited papers, showcasing their impact.

We are currently hiring EEs in various locations worldwide.

English Editing at MDPI

Our English Editing (EE) department consists of two main branches, Quality Control and Learning and Development, reflecting our priorities. We are continuously enhancing the quality of our English Editing services and have raised the relevant standards, which now extend to company-wide communications. English editors participate in international interviews, conduct English assessments, and provide colleagues with presentations on ways to improve their use of written and spoken English.

While expanding, the EE department has proactively refocused its efforts on the quality of our work and how the English Editing department can benefit the company more broadly. We currently have approximately 140 full-time English Editors based across five offices worldwide, supplemented by over 700 freelance English editors.

Our Manchester office serves as the hub for the EE Department, with EE Managers situated there, except for Kurtis Jackson, who serves as the Head of EE and is located in our Basel office. Manchester EEs play a critical role in establishing and developing EE teams in our other offices, overseeing management and recruitment. The EE department plays a vital role in MDPI’s operations, as it is the department that touches every published paper. If this work interests you, I encourage you to explore our available EE positions, whether you are seeking full-time or freelance opportunities.

Testimonials

“MDPI provides an excellent service compared to any other previously used services. It delivers fast and high-quality results but at an affordable price.” – Ardha Apriyanto, University of Potsdam

“In my role as a professor, I consider that MDPI Author Services offer an excellent quality in the editing of Western academic writing while maintaining the required standards of clarity, precision and rigor. Additionally, delivery times are fast compared to other available services.” – Jesus Insuasti, University of Nariño

Read more:

Coming Together for Science

STM and Frankfurt Book Fair

Attending STM

MDPI has been a proud sponsor of the STM Conference for several years. The STM Conference is a dynamic event featuring interactive sessions, expert panellists, idea-sharing, and ample networking opportunities. On 16 October, the event kicked off with arrival drinks, sponsored by MDPI, followed by a welcoming dinner, providing a great chance to connect and network with industry professionals. The following day was filled with speakers, sessions, and further opportunities to connect. STM exemplifies the collaborative spirit of the scientific community, with session topics including achieving open, visible, and impactful research at scale; maintaining research integrity in a rapidly changing world; and exploring the impact of ever-evolving technology in the scholarly community.

Meeting with Web of Science

On a personal note, one of the highlights of STM was a candid and productive conversation with Nandita Quaderi, Editor-in-Chief and SVP at Web of Science. During our discussion, we talked about MDPI, Web of Science, the IJERPH delisting, and ways of moving forward. This open conversation aimed at fostering better collaboration for the future.

“We discussed ways to improve our communication and collaboration.”

I appreciated our frank discussion and felt that Nandita wholeheartedly supports open access. She also expressed her appreciation for the monthly CEO Letter, which she sees as a way to add personality to the MDPI brand and provide insight into the great work we do at MDPI. While we highlighted the positives, we also discussed ways to improve our communication and collaboration moving forward. This meeting alone made the trip worthwhile, and I hope Nandita doesn’t mind my sharing that she found our chat to be “the most honest and constructive discussion” she’s had with someone from MDPI in recent years.

75th Frankfurt Book Fair


Jelena Milojevic (Book Editor, MDPI), Jovana Dubajic (Book Editor, MDPI), Evan Escamilla (Project Manager, MDPI), Laura Wagner (Head of Books, MDPI), and Jenny Knowles (Commissioning Editor, MDPI), at the Frankfurt Book Fair in Frankfurt am Main, Germany.

For the 75th time, the Frankfurter Buchmesse opened its doors in October to celebrate exciting stories and their authors. If you haven’t yet had the chance to visit the Frankfurt Book Fair, I highly recommend it. It’s the largest book fair in the world, attracting thousands of visitors from around the globe. This is the place to gain valuable industry insights from top-class publishing professionals, connect with publishers directly, and learn about the latest trends in publishing.

MDPI Books

Our Books team was also present at the Frankfurt Book Fair, networking and learning from various panels. Did you know that our MDPI Books department publishes OA Books?

The book publishing program includes monographs, book series, edited books and reprints of special issues and topical collections, among other book types.

If you have a book proposal you would like to discuss, please feel free to contact our Books team to understand the benefits and methods of publishing your next book with the OA model.

Closing Thoughts

MDPI Strategy Meeting

As the newly appointed CEO, this is my first year leading the MDPI Senior Management Strategy session. I saw it as an opportunity to explore what MDPI has the potential to become in the next five years. Guided by the vision of its founder and President, Dr. Shu-kun Lin, the company has accomplished remarkable feats over the past 27 years and currently holds the position as the world’s third-largest academic publisher, following Springer Nature and Elsevier.

Our primary objective is to build upon the milestones of the past decades and consolidate MDPI’s position as well-established publishing brand. The two-day meeting emphasized the importance of communicating MDPI’s values more actively via its brand and adopting a straightforward yet impactful approach to managing MDPI as a mature academic publisher.

“Our primary objective is to consolidate MDPI’s position as well-established publishing brand”

As the world’s number one open-access publisher, MDPI has long been a game-changer in the scholarly community, serving millions of authors. The challenge in being a trailblazer is the need to continuously improve and at the same time explore the next blue-ocean strategy, while also maintaining the smooth operation of the business. Our collection model, featuring guest-curated thematic topics in the form of Special Issues, has disrupted the industry. Other publishers closely study us and attempt to replicate our models. The future of this collection model is something we are actively addressing – while, of course, looking ahead to what comes next!

Stefan Tochev
Chief Executive Officer
MDPI AG

Back to TopTop